Denmark's troubled H. Lundbeck, which has been roiled by the failure of two late-stage trials and a delayed rollout of a U.S. sales force, is bidding goodbye to its chairman. Flemming Lindeløv's departure comes as a gesture to "restore calm," says the company. But with two big patents expiring in 2012 and 2014, analysts are looking for more success on the development side. Lundbeck has been under considerable pressure to acquire new therapies or find a bigger pharma company to merge with.
- see this release for more
Related Articles:
Merck, Lundbeck end gaboxadol development. Report
Teva, H. Lundbeck stop work on oral Copaxone. Report
Lundbeck's shares plunge as drug flunks Phase III. Report